Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12318187 | 1.00 | MAPT (0.40) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL12318851 | 0.90 | MAPT (0.36) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL14329855 | 0.89 | ALDH1A1 (0.35) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10265114 | 0.88 | ALDH1A1 (0.48) | MAPTALDH1A1IDH1NPC1CASP3 | |
| SCHEMBL16808292 | 0.88 | ALDH1A1 (0.48) | MAPTALDH1A1IDH1NPC1CASP3 | |
| SCHEMBL10205112 | 0.88 | MAPT (0.39) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL22726436 | 0.86 | PDE2A (0.40) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9327248 | 0.85 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9567734 | 0.85 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11431737 | 0.85 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MOLECULAR PROBES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | LIFE TECHNOLOGIES CORP (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-8865891-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| US-8318450-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120040380-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | MAPT 2586/4885PDE3A 1230/4885SLC22A6 2605/4885 |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | MAPT 2586/4885PDE3A 1230/4885SLC22A6 2605/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | MAPT 4465/4885PDE3A 29/4885SLC22A6 3564/4885 |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | MGAM, LCT, GAA | MAPT 2586/4885PDE3A 1230/4885SLC22A6 2605/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | MAPT 4465/4885PDE3A 29/4885SLC22A6 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.